← All trials
NCT03862157
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 27, 2019
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
- Leukemia, Myeloid
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Polycythemia Vera
- Thrombocythemia, Essential
- Leukemia, Neutrophilic, Chronic
- Leukemia, Myeloid, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.